reversibly inhibition

Mupirocin calcium hydrate 是从Pseudomonas fluorescens 中分离得到的，一种有口服活性的抗生素。它可逆地抑制异亮氨酸转移RNA，并抑制细菌蛋白和RNA 的合成起到抗菌作用。

Mupirocin (BRL-4910A) 是从Pseudomonas fluorescens 中分离得到的一种有口服活性的抗生素。它可逆地抑制异亮氨酸转移RNA，并抑制细菌蛋白和RNA 的合成起抗菌作用。

Bupivacaine hydrochloride (Vivacaine) 是NMDA 受体抑制剂，可用于慢性疼痛的研究。它可阻断钠、L-钙和钾通道，还阻断SCN5A 通道，IC50为 69.5 μM。

Emedastine (LY188695) 是一种可口服的，选择性和高亲和力的组胺 H1受体拮抗剂，Ki 值为 1.3 nM。它是苯并咪唑衍生物，可用于过敏性鼻炎、过敏性皮肤疾病和过敏性结膜炎的研究。

Articaine (Hoe-045 free base) 是一种含酯基的酰胺类麻醉剂，可逆地与神经内腔内电压门控钠通道的α亚基结合，能有效缓解疼痛。Articaine 通过抑制NF-ĸB 的激活和NLRP3炎症小体通路改善脂多糖 (LPS) 诱导的急性肾损伤。

Phaclofen (3-Amino-2-(4-chlorophenyl)propanephosphonic acid) 是一种选择性 GABAB receptor 拮抗剂，可部分拮抗（-）-巴氯芬的镇静作用，可逆地拮抗巴氯芬或GABA对豚鼠回肠和远端结肠胆碱能抽搐反应的抑制，可用于研究神进系统疾病。

Cudratricusxanthone A has potent anti-proliferative, antioxidative, and monoamine oxidase inhibitory effects, it also possesses anti-cancer activities and provide a basis for developing effective therapeutic agents to inhibit growth and metastasis of brea

para-amino-Blebbistatin is a more water-soluble form of (S)-4'-nitro-blebbistatin , which is a more stable and less phototoxic form of (-)-blebbistatin .1,2,3 (-)-Blebbistatin is a selective cell-permeable inhibitor of non-muscle myosin II ATPases that rapidly and reversibly inhibits Mg-ATPase activity and in vitro motility of non-muscle myosin IIA and IIB for several species (IC50s = 0.5-5 μM), while poorly inhibiting smooth muscle myosin (IC50 = 80 μM).2,3,4 Through these effects, it blocks apoptosis-related bleb formation, directed cell migration, and cytokinesis in vertebrate cells. However, prolonged exposure to blue light (450-490 nm) results in degradation of blebbistatin to an inactive product via cytotoxic intermediates, which may be problematic for its use in fluorescent live cell imaging applications.5,6 The addition of a 4'-amino group increases its water solubility, decreases the inherent fluorescence, stabilizes the molecule to circumvent its degradation by prolonged blue light exposure, and decreases its phototoxicity while retaining the in vitro and in vivo activity of blebbistatin.7 para-amino-Blebbistatin has the same stereochemistry as the active (-)-blebbistatin enantiomer. |1. Várkuti, B.H., Képiró, M., Horváth, I.á., et al. A highly soluble, non-phototoxic, non-fluorescent blebbistatin derivative. Sci. Rep. 6:26141, (2016).|2. Straight, A.F., Cheung, A., Limouze, J., et al. Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science 299(5613), 1743-1747 (2003).|3. Kovács, M., Tóth, J., Hetényi, C., et al. Mechanism of blebbistatin inhibition of myosin II. J. Biol. Chem. 279(34), 35557-35563 (2004).|4. Limouze, J., Straight, A.F., Mitchison, T., et al. Specificity of blebbistatin, an inhibitor of myosin II. J. Muscle Res. Cell Motil. 25(4-5), 337-341 (2004).|5. Kolega, J. Phototoxicity and photoinactivation of blebbistatin in UV and visible light. Biochem. Biophys. Res. Commun. 320(3), 1020-1025 (2004).|6. Sakamoto, T., Limouze, J., Combs, C.A., et al. Blebbistatin, a myosin II inhibitor, is photoinactivated by blue light. Biochemistry 44(2), 584-588 (2005).|7. Verhasselt, S., Roman, B.I., Bracke, M.E., et al. Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs. Eur. J. Med. Chem. 136, 85-103 (2017).